Y-MABS THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (form 8-K)

Item 2.01. Completion of Acquisition or Disposition of Assets

On January 21, 2021, Y-mAbs Therapeutics, Inc., (the "Company") closed its previously announced transaction with United Therapeutics Corporation ("United"), pursuant to which the Company sold its Priority Review Voucher ("PRV") to United in accordance with the terms of the Asset Purchase Agreement (the "Agreement") entered into by the parties on December 24, 2020. Upon closing, the Company received the cash proceeds of $105 million from United.

The PRV was granted in conjunction with the approval by the U.S. Food and Drug Administration ("FDA") of DANYELZA®, for the treatment of refractory/relapsed high-risk neuroblastoma.

The foregoing description of the Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Agreement. The Company intends to file a copy of the Agreement, potentially with certain portions subject to confidential treatment, with the Company's Annual Report on Form 10-K for the year ended December 31, 2020.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits



Exhibit No.   Description

104           Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses